Acquisition of immuno-oncology technology
Filed with ASX · · 4 pages · English
Earlier from Imugene
- Leslie Chong Appointed Chief Executive Officer
- Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
- Imugene Share Placement raises $3.2 million
- Imugene receives $1.3m R&D Tax Refund
- Imugene successfully completes preclinical animal studies
Later from Imugene
- Response to ASX Aware Query
- Imugene progresses mimotope platform
- BMC Cancer journal publishes encouraging HER-Vaxx research
- Intellectual Property Strengthened Around Lead Clinical Drug
- Half Year Report and Accounts
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene